Exciva
Manufacturing · Germany · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Hauptstraße 25, Heidelberg, Baden-Wuertt...Phone Number
+49 62216479990Website
www.exciva.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Exciva
Exciva is a biopharmaceutical company founded in 2016 by Drs Anton Bespalov, Hans Moebius and Rao Vepachedu to address neuropsychiatric symptoms in Alzheimer’s disease dementia and other brain disorders. Exciva uses its discovery potential, which has led to the combination of two CNS-active compounds to treat agitation in patients living with Alzheimer’s disease dementia.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Exciva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Exciva
Check out if Exciva is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Exciva had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Exciva has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Exciva recently announced quarterly report
Check if Exciva has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Exciva launches new products
Exciva, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Exciva as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Exciva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Exciva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Exciva.
Exciva financials insights
Gather financial insights about Exciva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$10M
2026
Series B
$59M
Exciva Tech Stack
A closer look at the technologies used by Exciva
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
Funding
Exciva News & Media
Heidelberg-based Exciva secures €51M to tackle agitation in Alzheimer's care
Alzheimer’s disease means memory loss for those affected. Beyond this, however, it is above all relatives and care staff who are impacted when the loss of cognitive abilities is accompanied by symptoms such as agitation, aggression, anxiety and depression, making home care impossible. This aspect of the disease is now gaining greater visibility through a major second financing round from EQT LifeScience, Gimv and Andera Partners with Exciva from Heidelberg.EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer's therapy into clinical Phase 2
Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease (AD) Financing was co-led by EQT Life Sciences out of its LSP Dementia Fund, together with Gimv, with participation from Fountain Healthcare...EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance its Alzheimer's therapy into clinical Phase 2
Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease (AD) Financing was co-led by EQT Life Sciences out of its LSP Dementia Fund, together with Gimv, with participation from Fountain Healthcare...Andera Partners' Portfolio Company Exciva Secures €51 Million Series B to ... - WebDisclosure
Andera Partners' portfolio company Exciva secures €51 million Series B funding for Alzheimer's-related agitation clinical program, led by Gimv and EQT Life Sciences
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Exciva
Sign Up For FreeTo access detailed company insights
Exciva is a biopharmaceutical company founded in 2016 by Drs Anton Bespalov, Hans Moebius and Rao Vepachedu to address neuropsychiatric symptoms in Alzheimer’s disease dementia and other brain disorders. Exciva uses its discovery potential, which has led to the combination of two CNS-active compounds to treat agitation in patients living with Alzhe... Read More
